An insight into JAK-STAT signalling in dermatology

J A Palanivel; A E Macbeth; N C Chetty; N J Levell

doi:10.1111/ced.12273

An insight into JAK-STAT signalling in dermatology

J A Palanivel, A E Macbeth, N C Chetty, N J Levell

Norwich Medical School

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Many emerging studies have implicated the Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signalling mechanism in disease pathogenesis. This signalling pathway is involved in haematopoiesis and immune development. Mutations in genes regulating JAK-STAT signalling can cause common inflammatory disorders and myeloproliferative disorders. JAK and STAT inhibitors are new management tools for disorders such as myelofibrosis and rheumatoid arthritis. Evidence suggests that the cytokine components of the JAK-STAT pathways play a crucial role in common skin disorders, including psoriasis and atopic dermatitis. We present an overview for the clinical dermatologist of the significance of these signalling pathways in various skin disorders, and introduce the potential application of JAK and STAT inhibition as a new therapeutic tool in dermatology.

Original language	English
Pages (from-to)	513-518
Number of pages	6
Journal	Clinical and Experimental Dermatology
Volume	39
Issue number	4
Early online date	13 May 2014
DOIs	https://doi.org/10.1111/ced.12273
Publication status	Published - Jun 2014

Keywords

Humans
Janus Kinases
Protein Kinase Inhibitors
STAT Transcription Factors
Signal Transduction
Skin Diseases
Journal Article
Research Support, Non-U.S. Gov't
Review

Access to Document

10.1111/ced.12273

Cite this

@article{aafe8a70464e4f89a4a95faa2be8c321,

title = "An insight into JAK-STAT signalling in dermatology",

abstract = "Many emerging studies have implicated the Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signalling mechanism in disease pathogenesis. This signalling pathway is involved in haematopoiesis and immune development. Mutations in genes regulating JAK-STAT signalling can cause common inflammatory disorders and myeloproliferative disorders. JAK and STAT inhibitors are new management tools for disorders such as myelofibrosis and rheumatoid arthritis. Evidence suggests that the cytokine components of the JAK-STAT pathways play a crucial role in common skin disorders, including psoriasis and atopic dermatitis. We present an overview for the clinical dermatologist of the significance of these signalling pathways in various skin disorders, and introduce the potential application of JAK and STAT inhibition as a new therapeutic tool in dermatology.",

keywords = "Humans, Janus Kinases, Protein Kinase Inhibitors, STAT Transcription Factors, Signal Transduction, Skin Diseases, Journal Article, Research Support, Non-U.S. Gov't, Review",

author = "Palanivel, {J A} and Macbeth, {A E} and Chetty, {N C} and Levell, {N J}",

note = "{\textcopyright} 2014 British Association of Dermatologists.",

year = "2014",

month = jun,

doi = "10.1111/ced.12273",

language = "English",

volume = "39",

pages = "513--518",

journal = "Clinical and Experimental Dermatology",

issn = "0307-6938",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - An insight into JAK-STAT signalling in dermatology

AU - Palanivel, J A

AU - Macbeth, A E

AU - Chetty, N C

AU - Levell, N J

PY - 2014/6

Y1 - 2014/6

N2 - Many emerging studies have implicated the Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signalling mechanism in disease pathogenesis. This signalling pathway is involved in haematopoiesis and immune development. Mutations in genes regulating JAK-STAT signalling can cause common inflammatory disorders and myeloproliferative disorders. JAK and STAT inhibitors are new management tools for disorders such as myelofibrosis and rheumatoid arthritis. Evidence suggests that the cytokine components of the JAK-STAT pathways play a crucial role in common skin disorders, including psoriasis and atopic dermatitis. We present an overview for the clinical dermatologist of the significance of these signalling pathways in various skin disorders, and introduce the potential application of JAK and STAT inhibition as a new therapeutic tool in dermatology.

AB - Many emerging studies have implicated the Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signalling mechanism in disease pathogenesis. This signalling pathway is involved in haematopoiesis and immune development. Mutations in genes regulating JAK-STAT signalling can cause common inflammatory disorders and myeloproliferative disorders. JAK and STAT inhibitors are new management tools for disorders such as myelofibrosis and rheumatoid arthritis. Evidence suggests that the cytokine components of the JAK-STAT pathways play a crucial role in common skin disorders, including psoriasis and atopic dermatitis. We present an overview for the clinical dermatologist of the significance of these signalling pathways in various skin disorders, and introduce the potential application of JAK and STAT inhibition as a new therapeutic tool in dermatology.

KW - Humans

KW - Janus Kinases

KW - Protein Kinase Inhibitors

KW - STAT Transcription Factors

KW - Signal Transduction

KW - Skin Diseases

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1111/ced.12273

DO - 10.1111/ced.12273

M3 - Article

C2 - 24825142

VL - 39

SP - 513

EP - 518

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

IS - 4

ER -